GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (NAS:AWH) » Definitions » Cyclically Adjusted Price-to-FCF

Aspira Womens Health (Aspira Womens Health) Cyclically Adjusted Price-to-FCF : (As of May. 03, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aspira Womens Health Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aspira Womens Health Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Aspira Womens Health's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Cyclically Adjusted Price-to-FCF Chart

Aspira Womens Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aspira Womens Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aspira Womens Health's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Aspira Womens Health's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspira Womens Health's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Cyclically Adjusted Price-to-FCF falls into.



Aspira Womens Health Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Aspira Womens Health's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Aspira Womens Health's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.332/129.4194*129.4194
=-0.332

Current CPI (Dec. 2023) = 129.4194.

Aspira Womens Health Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -1.475 99.695 -1.915
201406 -1.595 100.560 -2.053
201409 -2.294 100.428 -2.956
201412 -1.730 99.070 -2.260
201503 -1.587 99.621 -2.062
201506 -1.760 100.684 -2.262
201509 -1.311 100.392 -1.690
201512 -1.561 99.792 -2.024
201603 -1.604 100.470 -2.066
201606 -1.132 101.688 -1.441
201609 -0.841 101.861 -1.069
201612 -0.799 101.863 -1.015
201703 -0.678 102.862 -0.853
201706 -0.478 103.349 -0.599
201709 -0.470 104.136 -0.584
201712 -0.539 104.011 -0.671
201803 -0.595 105.290 -0.731
201806 -0.525 106.317 -0.639
201809 -0.462 106.507 -0.561
201812 -0.468 105.998 -0.571
201903 -0.627 107.251 -0.757
201906 -0.704 108.070 -0.843
201909 -0.538 108.329 -0.643
201912 -0.444 108.420 -0.530
202003 -0.543 108.902 -0.645
202006 -0.537 108.767 -0.639
202009 -0.467 109.815 -0.550
202012 -0.717 109.897 -0.844
202103 -0.731 111.754 -0.847
202106 -0.882 114.631 -0.996
202109 -1.073 115.734 -1.200
202112 -1.027 117.630 -1.130
202203 -1.372 121.301 -1.464
202206 -0.846 125.017 -0.876
202209 -0.969 125.227 -1.001
202212 -0.861 125.222 -0.890
202303 -0.687 127.348 -0.698
202306 -0.407 128.729 -0.409
202309 -0.340 129.860 -0.339
202312 -0.332 129.419 -0.332

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aspira Womens Health  (NAS:AWH) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Aspira Womens Health Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspira Womens Health (Aspira Womens Health) Business Description

Traded in Other Exchanges
N/A
Address
12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.
Executives
Nicole Sandford director 12117 BEE CAVES RD BLDG 3, STE 100, AUSTIN TX 78738
Minh Hoang Merchant officer: General Counsel & Secretary 1210 AVONDALE ROAD, HILLSBOROUGH CA 94010
Torsten Hombeck officer: Chief Financial Officer 529 W 42ND ST #6V, NEW YORK NY 10036
Celeste Rachelle Fralick director 2801 MESA ROAD, LUBBOCK TX 79403
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Stefanie L. Cavanaugh director 1120 S CAPITAL OF TX HWY, BLDG 1, STE 300, AUSTIN TX 78746
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Ryan Thinh Phan officer: CSO & COO 327 CARLTON AVE, LOS GATOS CA 95032
Jannie Prestridge Herchuk director 6331 LAVENDALE AVE, DALLAS TX 75230
Winfred Parnell director 6734 TALMADGE LANE, DALLAS TX 75230
Marlene Mclennan officer: Interim Chief Financial Office 400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Ruby Sharma director 24 ARNOLD DRIVE, PRINCETON JCT. NJ 08550
Robert D Auerbach director C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Valerie Barber Palmieri director, officer: President and CEO 63 INDIAN LEDGE RD., MONROE CT 06468

Aspira Womens Health (Aspira Womens Health) Headlines